BC
BCTX
BriaCell Therapeutics Corp.
$3.80
-2.06%
$28.1M
No data for this timeframe.
Vol
Market Cap$28.1M
Cap SizeNano Cap
Inst. Holders2 funds
Inst. Value$24.9K
Inst. Activity1 buys / 0 sells
Reddit Sentiment63° Warm
Recent Activity
Inst.
MORGAN STANLEY — DOUBLED
3,501 shares ($24.9K)
May 15, 2026
other
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™
<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2026 (GLOBE NEWSWIRE) --
Analyst Ratings
1Strong Buy
3Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Aug 27, 2025 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Apr 22, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Feb 3, 2025 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Dec 12, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Dec 3, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $24.9K | DOUBLED |
| WELLS FARGO & COMPANY/MN | $7.00 | — |
Reddit Sentiment
63°
Warm
Bearish
Neutral
Bullish
2 institutional holders with $24.9K total value (3,502 shares) as of 2025-Q4. Top holders: MORGAN, WELLS. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 3,501 | $24.9K | 100.0% | DOUBLED +2971.1% |
| 2 | WELLS FARGO & COMPANY/MN | 1 | $7.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | DOUBLED | 114 | 3,501 | +2971.1% | $24.9K | 2025-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Aug 2025): 80% buy across 5 analysts — 1 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2025-10-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-07-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Aug 27, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 22, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 3, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Dec 12, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Dec 3, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Oct 3, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Sep 19, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Sep 11, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 4, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 24, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jan 1, 2023 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Dec 1, 2022 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Nov 1, 2022 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Oct 1, 2022 | 1 | 3 | 1 | 0 | 0 | 80% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
63°
Warm
Bearish
Neutral
Bullish
4 mentions
2 bullish
0 bearish
4 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 18, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 18, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 7, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| May 7, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
May 15, 2026
other
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™
<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL)
May 15, 2026
short_volume
Short Volume: BCTX — 76.3% short (0.6M / 0.8M)
Short: 614,977 | Exempt: 50,374 | TRF Vol: 806,147 | Short Ratio: 76.3% | Off-exchange volume (dark pool + OTC)
May 14, 2026
other
BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer
<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL)
May 13, 2026
contract
BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL)
May 12, 2026
other
BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients
<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL)
May 6, 2026
fda
BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer
<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 06, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL)
Apr 27, 2026
routine
BriaCell Announces Six Clinical Data Presentations at ASCO 2026
<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL
Apr 21, 2026
fda
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models
<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL
Apr 20, 2026
fda
BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting
<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, April 20, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL
Mar 31, 2026
m_and_a
BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License
<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW
Mar 18, 2026
fda
BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference
<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL
Mar 10, 2026
routine
BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting
<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, March 10, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL
Mar 5, 2026
earnings
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
<p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- <strong>BriaCell Therapeutics Corp. (Nasdaq: BCT